



## General description

Cytarabine is a pyrimidine nucleoside analogue antineoplastic agent used in the treatment of leukaemias and lymphomas.

INN	Cytarabine
ATC codes	L01BC01
Medicine type	Chemical agent
EML status history	<p>First added in 1979 (TRS 641) for Lymphoid leukaemia, not elsewhere classified</p> <p>Added in 1979 (TRS 641) for Myeloid leukaemia</p> <p>Added in 1979 (TRS 641) for Acute myeloid leukaemia with recurrent genetic abnormalities</p> <p>Added in 1979 (TRS 641) for Burkitt lymphoma including Burkitt leukaemia</p> <p>Added in 1979 (TRS 641) for Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-positive</p> <p>Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-negative</p> <p>Added in 2023 (TRS 1049) for Langerhans cell histiocytosis</p>
Wikipedia	<a href="#">Cytarabine</a> 
DrugBank	<a href="#">Cytarabine</a> 

## Recommendations

Section Cytotoxic medicines

Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial  
 Parenteral > General injections > unspecified: 100 mg in vial powder for injection

### Indications

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Acute myeloid leukaemia with recurrent genetic abnormalities

Burkitt lymphoma including Burkitt leukaemia

Unspecified malignant neoplasms of ill-defined or unspecified sites

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

Langerhans cell histiocytosis



